Prominent THC profile featured in PharmaCielo’s new Colombian cannabis strains

Ellen Samek - thegrowthop.com Posted 5 years ago
image

The Colombian subsidiary of Canadian parent company PharmaCielo Ltd. has obtained approval from the country’s national cultivar registry to list an additional 10 cannabis strains, all of which have a prominent tetrahydrocannabinol (THC) profile.

Listing approval was received by PharmaCielo Colombia Holdings S.A.S., notes a statement from PharmaCielo, a Canada-headquartered global company with a focus on ethical and sustainable processing and supplying of all-natural, medicinal-grade cannabis oil extracts and related products to large channel distributors.

 

  • Mutual respect cornerstone of Indigenous involvement in the cannabis space
  • PharmaCielo approved for cultivar registration of 10 proprietary cannabis strains in Colombia
  • PharmaCielo establishes joint venture with Mino Labs to bring medicinal cannabis oil to Mexico

 

The new THC-dominant strains, including a 1:1 THC to CBD ratio offering, almost double PharmaCielo’s 11 previously approved strains in the registry. Another 10 strain applications are currently awaiting approval, the company press release states.

The recent approvals make PharmaCielo what the company claims is the largest holder of approved strains in Colombia, as well as paves “the way for the commercial registration, production and sale of the 20 unique strains,” the statement notes.

Beyond the new listings and applications, PharmaCielo recently registered with the national cultivar registry a special CBD strain with a 20:1 ratio profile, reports the company. Demand for this type of strain is expected to rise in light of the growing medical use of CBD-dominant cannabis oils and derived products, it adds.

 

 

“The medical community has diverse requirements for cannabis oil extracts based on specific needs, and as both CBD and THC are increasingly recognized for their medicinal role, the 1:1 ratio strain that we developed and received approval for makes a very significant contribution to the range of natural medicinal options,” suggests Delon Human, global head of health and innovation with PharmaCielo.

“The range of the strains now available at our disposal for commercial production is an important advantage that sets the company apart in both the Colombian and global marketplaces,” comments Federico Cock-Correa, president and CEO of PharmaCielo Colombia Holdings.

Noting the lengthy registration process for completing strain registration in Colombia, sometimes as long as several years, PharmaCielo has received strain approval representing a diverse range of chemotypes, with various ratios of CBD to THC.

Want to keep up to date on what’s happening in the world of cannabis?  Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network.